Drug Discovery World

MARCH 23, 2023

Aldena Therapeutics, a biotech company that is pioneering siRNA-based therapies for dermatological indications, has updated its immuno-dermatology pipeline, appointed a Scientific Advisory Board (SAB), and announced $30 million financing by Medicxi. appeared first on Drug Discovery World (DDW).

Dermatology 52

Dermatology Life Science Production Scientist 52

Outsourcing Pharma

MAY 23, 2022

With Veeva Link for Key People, LEO Pharma is looking to deepen its efforts to engage with knowledgeable medical professionals in the dermatology community.

Dermatology 52

Dermatology Development Drugs Regulation 52

pharmaphorum

NOVEMBER 11, 2021

KNUTSFORD, United Kingdom — Fishawack Health welcomes FIDE, an independent organization providing its clients with insight from clinical key opinion leaders in inflammatory dermatology. Kenneth B Gordon, MD, Professor and Chair of Dermatology at the Medical College of Wisconsin. November 10, 2021, UK.

Dermatology 98

Dermatology Life Science Marketing Production 98

WCG Clinical

SEPTEMBER 20, 2023

Welcome to the recorded session of ‘Optimizing Endpoint Assessments for Dermatology Studies.’ In this insightful webinar, we take a deep dive into dermatology trials and discuss how standardizing rater qualification and training can solve common challenges and protect the quality and integrity of endpoint data.

Dermatology 52

Dermatology Trials Development Clinical Trials 52

WCG Clinical

OCTOBER 9, 2023

The dermatology market is embarking on tremendous growth and sponsors need to be ready. Over the last 12 months, dermatology-focused studies have increased by roughly 20%, with top focus areas including psoriasis, atopic dermatitis, and alopecia. This rapid growth brings new challenges. Efficiency and speed are critical.

Dermatology 59

Dermatology Trials Marketing Clinical Trials 59

BioTech 365

DECEMBER 3, 2020

DermTech Presents Updates in Precision Medicine at 2020 Dermatology Drug Development Summit DermTech Presents Updates in Precision Medicine at 2020 Dermatology Drug Development Summit LA JOLLA, Calif.–(BUSINESS –(BUSINESS WIRE)–DermTech, Inc.

Dermatology 52

Dermatology Medicine Development Drugs 52

Drug Discovery World

MARCH 13, 2023

LEO Pharma and ICON have formed a strategic partnership that will enable LEO to offer clinical trials within medical dermatology that are patient-centric and cost effective. The partnership will operate under the acronym of PACE, reflecting the requirement to move quickly to address today’s clinical development challenges.

Dermatology 52

Dermatology Trials Clinical Trials Clinical Trials 52

WCG Clinical

MARCH 30, 2023

WCG’s InvestigatorSpace® offers customizable training solutions to bring accurate and detailed training to life while reducing the time spent on developing assets by an average of 60%. WCG collaborated with study teams and clinical experts to develop the training modules.

Dermatology 52

Dermatology Clinical Trials Clinical Trials Trials 52

BioTech 365

MAY 20, 2021

Pyramid Biosciences Announces First Patients Dosed in Phase 1 Clinical Program for Dermatology Pyramid Biosciences Announces First Patients Dosed in Phase 1 Clinical Program for Dermatology PBI-100 is a topical treatment being developed for people living with mild to moderate … Continue reading →

Dermatology 52

Dermatology Development 52

Outsourcing Pharma

DECEMBER 13, 2021

The pharmaceutical company currently has several promising treatments in development for gastroenterological, dermatological, and cardiological conditions.

Cardiology 145

Cardiology Dermatology Development Regulation 145

Pharmaceutical Technology

JANUARY 19, 2023

Concert’s patent portfolio includes oral Janus kinases JAK1/2 inhibitor, deuruxolitinib, to treat Alopecia Areata, an autoimmune dermatological disease. The company also noted that the deal will strengthen its global dermatology franchise with the addition of a late-stage product in an area with significant unmet need.

Dermatology 147

Dermatology Sales Drugs Production 147

Pharmaceutical Commerce

FEBRUARY 20, 2024

As part of the agreement, Novo will be paid both development and commercial milestone payments for NN-8828, is currently in Phase II of non-dermatological indications.

Dermatology 52

Dermatology Licensing Licensing Antibody 52

XTalks

AUGUST 2, 2023

Verrica Pharmaceuticals is a dermatology therapeutics company developing medications for skin diseases that require medical interventions. Tune into this episode to learn more about YCANTH and its approval, as well as the changing landscape of dermatology, from Dr. Eichenfield.

Life Science 52

Life Science FDA Approval Dermatology Pharmacy 52

BioTech 365

SEPTEMBER 23, 2020

23, 2020 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that positive results from the two pivotal Phase III CAMP (Cantharidin … Continue reading →

Dermatology 40

Dermatology Trials Development 40

Medical Xpress

MARCH 28, 2023

Adults with atopic dermatitis (AD) have an increased risk for developing melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC), with significantly higher risks seen for moderate-to-severe versus mild AD, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 17 to 21 in New Orleans. (..)

Dermatology 108

Dermatology Development 108

Outsourcing Pharma

MARCH 14, 2023

A strategic partnership between LEO Pharma and ICON plc, a clinical development company, was announced on March 10.

Dermatology 52

Dermatology Clinical Development Development 52

Pharmaceutical Technology

APRIL 19, 2023

The drug is taken once a day and is currently being developed for the treatment of inflammatory dermatoses, mainly in hair-bearing body areas such as the face, the trunk and the scalp. The regulator has set 16 December 2023 as a prescription drug user fee act (PDUFA) target action date for the decision on the application.

Dermatology 130

Dermatology Trials Drugs Regulation 130

Pharmaceutical Technology

FEBRUARY 28, 2023

KFA-115 is under clinical development by Novartis and currently in Phase I for Melanoma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Generic Pharmaceutical 172

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 172

Pharmaceutical Technology

MARCH 27, 2023

Regenerative medicines in early-stage development (preclinical, discovery, or investigational new drug [IND]/ clinical trial application [CTA] filed status) have seen a change in drug targets compared to therapies in late-stage development (Phase II to pre-registration stage).

Medicine 246

Medicine Gene Therapy Gene Dermatology 246

The Pharma Data

OCTOBER 29, 2020

30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. vice president of immunology development at Lilly.

Dermatology 52

Dermatology Development Medicine Clinical Trials 52

pharmaphorum

APRIL 29, 2022

An artificial intelligence-powered digital tool for diagnosing skin cancers developed by Skin Analytics has been cleared in the UK as a Class IIA medical device, setting up broader use of the technology in patient assessments.

Dermatology 145

Dermatology Containment Marketing Development 145

Pharmaceutical Technology

APRIL 17, 2023

The company will provide regulatory advice to Incannex, and manage clinical trials to develop CannQuit and ReneCann products to treat addiction and immune-disordered skin diseases. The company will help in managing the clinical trials of the products once the regulators provide approvals for the proposed research and development programmes.

Dermatology 130

Dermatology Clinical Trials Clinical Trials Production 130

Drug Discovery World

MARCH 18, 2024

IL-23 plays a critical role in pathogenic T-cell activation in moderate-to-severe PsO and underpins the inflammatory response in PsO and other dermatological, rheumatological and gastroenterological IL-23-mediated diseases. JNJ-2113 is the first and only investigational targeted oral peptide designed to block the IL-23 receptor.

Dermatology 52

Dermatology Drugs Clinical Trials Clinical Trials 52

pharmaphorum

MARCH 24, 2021

After 27 years at Bayer, Jörg Möller has moved to LEO Pharma as the company’s EVP, global research and development. The post LEO Pharma’s new R&D lead on driving agility in drug development appeared first on. Is it a disease that has a high symptomatic disease burden, but is otherwise more of a nuisance?”

Development 52

Development Dermatology Drugs Research 52

The Pharma Data

OCTOBER 1, 2021

The research, which spans clinical, health economics and outcomes research, translational, clinical pharmacology and preclinical presentations, highlights the breadth and depth of the company’s data on deucravacitinib, a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor, also because the emerging dermatology pipeline.

Dermatology 52

Dermatology Trials Clinical Development Research 52

XTalks

APRIL 17, 2023

These results are very promising for patients with atopic dermatitis,” said Jonathan Silverberg, MD, professor of dermatology at George Washington University School of Medicine & Health Sciences and co-investigator of the studies, in the company’s press release.

Dermatology 97

Dermatology Antibody Clinical Trials Clinical Trials 97

Pharmaceutical Technology

DECEMBER 5, 2022

Incyte has signed a partnership and licence agreement with CMS subsidiary CMS Aesthetics to develop and market ruxolitinib cream to treat autoimmune and inflammatory dermatologic ailments in Greater China and some Southeast Asian countries. Incyte will also receive royalty payments on the net product sales in the territory of CMS.

Dermatology 130

Dermatology FDA Approval Sales Production 130

Pharmaceutical Technology

FEBRUARY 28, 2023

KFA-115 is under clinical development by Novartis and currently in Phase I for Malignant Mesothelioma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

pharmaphorum

SEPTEMBER 16, 2022

Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching, dry skin, severe pain, and inflammation – all of which create considerable stress in the daily lives of patients and often negatively affect their day-to-day and long-term well-being. Findings presented at EADVC 2022.

Dermatology 100

Dermatology Trials Drugs Development 100

ACRP blog

OCTOBER 3, 2023

Edited by Gary Cramer The post Internship Program Boosts Clinical Research Workforce Development in Pennsylvania appeared first on ACRP. Every department that had an intern this past summer is asking for the opportunity to have an intern next year, Gardner said, and other departments are asking to participate. “It

Clinical Research 59

Clinical Research Research Development Medicine 59

XTalks

APRIL 26, 2023

He began his career in business development and commercial strategy roles at Genentech. Poster Presentation, Innovations in Dermatology Conference, Las Vegas, NV, November 3-5, 2022. Dermatology. Dermatology. Hear more about the innovative technology and application of DermaSensor in this episode. 2004;208:27-31.

Life Science 52

Life Science Dermatology Clinical Trials Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 28, 2023

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Paroxysmal Nocturnal Hemoglobinuria. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Glomerulonephritis. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

Pharmaceutical Technology

FEBRUARY 24, 2023

(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Contract Manufacturing 100

Contract Manufacturing Dermatology Hormones Production 100

pharmaphorum

DECEMBER 1, 2021

The post Sanofi snaps up acne vaccine developer Origimm Bio appeared first on. It will highlight vaccines for pneumococcal disease, meningitis, respiratory syncytial virus (RSV), influenza, and chlamydia. Photo by Scott Webb on Unsplash.

Vaccination 105

Vaccination Vaccine Development Hormones 105

pharmaphorum

SEPTEMBER 8, 2022

Furthering DiME’s previous work on digital clinical measures, nocturnal scratch’s more widespread implementation aims to establish a firmer digital groundwork for future clinical research, technology development, and reimbursement decisions in the dermatological field, and thereby improve the lives of AD patients and caregivers.

Dermatology 52

Dermatology Production Radiology Development 52